Thrombocytopenia - Pipeline Review, H2 2016

  • ID: 3961140
  • Report
  • 163 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc.
  • arGEN-X BV
  • Boehringer Ingelheim GmbH
  • Immunomedics, Inc.
  • Neumedicines Inc.
  • PhytoHealth Corporation
  • MORE
Thrombocytopenia - Pipeline Review, H2 2016

The latest Pharmaceutical and Healthcare disease pipeline guide Thrombocytopenia – Pipeline Review, H2 2016, provides an overview of the Thrombocytopenia (Hematological Disorders) pipeline landscape.

Thrombocytopenia is characterized by an abnormally low amount of platelets Low platelet levels occur due to less production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream or in the spleen or liver. Symptoms include bleeding in the mouth and gums, bruising, nosebleeds and rashes. Treatment includes transfusion of platelets to stop or prevent bleeding.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Thrombocytopenia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thrombocytopenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thrombocytopenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 10, 6, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.Thrombocytopenia.

Thrombocytopenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombocytopenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Thrombocytopenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thrombocytopenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thrombocytopenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thrombocytopenia (Hematological Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thrombocytopenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thrombocytopenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc.
  • arGEN-X BV
  • Boehringer Ingelheim GmbH
  • Immunomedics, Inc.
  • Neumedicines Inc.
  • PhytoHealth Corporation
  • MORE
Introduction

Thrombocytopenia Overview

Therapeutics Development

Pipeline Products for Thrombocytopenia - Overview

Pipeline Products for Thrombocytopenia - Comparative Analysis

Thrombocytopenia - Therapeutics under Development by Companies

Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes

Thrombocytopenia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Thrombocytopenia - Products under Development by Companies

Thrombocytopenia - Products under Investigation by Universities/Institutes

Thrombocytopenia - Companies Involved in Therapeutics Development

3SBio Inc.

AkaRx Inc

Amarillo Biosciences, Inc.

Amgen Inc.

arGEN-X BV

BioLineRx, Ltd.

Biotest AG

Boehringer Ingelheim GmbH

Bolder Biotechnology, Inc.

Bristol-Myers Squibb Company

Cellerant Therapeutics, Inc.

Genosco

Hansa Medical AB

Immunomedics, Inc.

Intas Pharmaceuticals Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Merck & Co., Inc.

Momenta Pharmaceuticals, Inc.

Myelo Therapeutics GmbH

Neumedicines Inc.

Novartis AG

Pfizer Inc.

PhytoHealth Corporation

Prophylix Pharma AS

Protalex, Inc.

Rigel Pharmaceuticals, Inc.

Shionogi & Co., Ltd.

Shire Plc

STATegics, Inc.

UCB SA

ViroMed Co Ltd

Thrombocytopenia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Antibody for Autoimmune Disorders and Inflammation - Drug Profile

ARGX-113 - Drug Profile

avatrombopag - Drug Profile

BBT-059 - Drug Profile

BI-655064 - Drug Profile

BL-8040 - Drug Profile

BMS-986004 - Drug Profile

BT-595 - Drug Profile

CLT-009 - Drug Profile

eltrombopag olamine - Drug Profile

eltrombopag olamine - Drug Profile

fostamatinib disodium - Drug Profile

GL-2045 - Drug Profile

GSK-2285921 - Drug Profile

Hetrombopag Olamine - Drug Profile

interferon alfa - Drug Profile

lusutrombopag - Drug Profile

M-281 - Drug Profile

MK-8723 - Drug Profile

Monoclonal Antibody to Agonize Thrombopoietin Receptor for Thrombocytopenia - Drug Profile

Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile

Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile

Myelo-001 - Drug Profile

NMIL-121 - Drug Profile

Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile

PEG-VM501 - Drug Profile

PHN-013 - Drug Profile

PRTX-100 - Drug Profile

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile

romiplostim - Drug Profile

romiplostim biosimilar - Drug Profile

SHP-652 - Drug Profile

SKIO-703 - Drug Profile

Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile

Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile

STST-4 - Drug Profile

thrombopoietin - Drug Profile

Tromplate - Drug Profile

TXA-302 - Drug Profile

UCB-7665 - Drug Profile

veltuzumab - Drug Profile

Thrombocytopenia - Dormant Projects

Thrombocytopenia - Discontinued Products

Thrombocytopenia - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Thrombocytopenia, H2 2016

Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2016

Thrombocytopenia - Pipeline by 3SBio Inc., H2 2016

Thrombocytopenia - Pipeline by AkaRx Inc, H2 2016

Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H2 2016

Thrombocytopenia - Pipeline by Amgen Inc., H2 2016

Thrombocytopenia - Pipeline by arGEN-X BV, H2 2016

Thrombocytopenia - Pipeline by BioLineRx, Ltd., H2 2016

Thrombocytopenia - Pipeline by Biotest AG, H2 2016

Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H2 2016

Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H2 2016

Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016

Thrombocytopenia - Pipeline by Genosco, H2 2016

Thrombocytopenia - Pipeline by Hansa Medical AB, H2 2016

Thrombocytopenia - Pipeline by Immunomedics, Inc., H2 2016

Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H2 2016

Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016

Thrombocytopenia - Pipeline by Merck & Co., Inc., H2 2016

Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016

Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H2 2016

Thrombocytopenia - Pipeline by Neumedicines Inc., H2 2016

Thrombocytopenia - Pipeline by Novartis AG, H2 2016

Thrombocytopenia - Pipeline by Pfizer Inc., H2 2016

Thrombocytopenia - Pipeline by PhytoHealth Corporation, H2 2016

Thrombocytopenia - Pipeline by Prophylix Pharma AS, H2 2016

Thrombocytopenia - Pipeline by Protalex, Inc., H2 2016

Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016

Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H2 2016

Thrombocytopenia - Pipeline by Shire Plc, H2 2016

Thrombocytopenia - Pipeline by STATegics, Inc., H2 2016

Thrombocytopenia - Pipeline by UCB SA, H2 2016

Thrombocytopenia - Pipeline by ViroMed Co Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Thrombocytopenia - Dormant Projects, H2 2016

Thrombocytopenia - Dormant Projects (Contd..1), H2 2016

Thrombocytopenia - Dormant Projects (Contd..2), H2 2016

Thrombocytopenia - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Thrombocytopenia, H2 2016

Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc.
  • AkaRx Inc
  • Amarillo Biosciences, Inc.
  • Amgen Inc.
  • arGEN-X BV
  • BioLineRx, Ltd.
  • Biotest AG
  • Boehringer Ingelheim GmbH
  • Bolder Biotechnology, Inc.
  • Bristol-Myers Squibb Company
  • Cellerant Therapeutics, Inc.
  • Genosco
  • Hansa Medical AB
  • Immunomedics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Momenta Pharmaceuticals, Inc.
  • Myelo Therapeutics GmbH
  • Neumedicines Inc.
  • Novartis AG
  • Pfizer Inc.
  • PhytoHealth Corporation
  • Prophylix Pharma AS
  • Protalex, Inc.
  • Rigel Pharmaceuticals, Inc.
  • Shionogi & Co., Ltd.
  • Shire Plc
  • STATegics, Inc.
  • UCB SA
  • ViroMed Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll